Organogenesis Holdings Inc. [NASDAQ: ORGO] slipped around -0.02 points on Thursday, while shares priced at $16.39 at the close of the session, down -0.12%. The company report on May 27, 2021 that Crocs Set to Join S&P MidCap 400 and Organogenesis to Join S&P SmallCap 600.
S&P SmallCap 600 constituent Crocs Inc. (NASD:CROX) will replace Cantel Medical Corp. (NYSE:CMD) in the S&P MidCap 400, and Organogenesis Holdings Inc. (NASD: ORGO) will replace Crocs in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 2, 2021. STERIS plc (NYSE: STE) is acquiring Cantel Medical in a deal expected to be completed soon pending final closing conditions.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:.
Organogenesis Holdings Inc. stock is now 117.66% up from its year-to-date (YTD) trading value. ORGO Stock saw the intraday high of $16.49 and lowest of $15.755 per share. The company’s 52-week high price is 24.34, which means current price is +129.85% above from all time high which was touched on 04/09/21.
Compared to the average trading volume of 1.10M shares, ORGO reached a trading volume of 2765568 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Organogenesis Holdings Inc. [ORGO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ORGO shares is $26.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ORGO stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for Organogenesis Holdings Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 10, 2020. While these analysts kept the previous recommendation, Credit Suisse dropped their target price from $9 to $10. The new note on the price target was released on August 26, 2019, representing the official price target for Organogenesis Holdings Inc. stock. Previously, the target price had yet another raise to $9, while Credit Suisse analysts kept a Outperform rating on ORGO stock.
The Average True Range (ATR) for Organogenesis Holdings Inc. is set at 1.47, with the Price to Sales ratio for ORGO stock in the period of the last 12 months amounting to 5.57. The Price to Book ratio for the last quarter was 13.33, with the Price to Cash per share for the same quarter was set at 0.60. Price to Free Cash Flow for ORGO in the course of the last twelve months was 3015.53 with Quick ratio for the last quarter at 2.10.
How has ORGO stock performed recently?
Organogenesis Holdings Inc. [ORGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.44. With this latest performance, ORGO shares dropped by -21.73% in over the last four-week period, additionally plugging by 215.19% over the last 6 months – not to mention a rise of 289.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORGO stock in for the last two-week period is set at 40.84, with the RSI for the last a single of trading hit 38.99, and the three-weeks RSI is set at 43.17 for Organogenesis Holdings Inc. [ORGO]. The present Moving Average for the last 50 days of trading for this stock 19.61, while it was recorded at 17.34 for the last single week of trading, and 10.62 for the last 200 days.
Organogenesis Holdings Inc. [ORGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Organogenesis Holdings Inc. [ORGO] shares currently have an operating margin of +8.10 and a Gross Margin at +71.98. Organogenesis Holdings Inc.’s Net Margin is presently recorded at +5.31.
Return on Total Capital for ORGO is now 14.67, given the latest momentum, and Return on Invested Capital for the company is 10.24. Return on Equity for this stock inclined to 17.80, with Return on Assets sitting at 6.97. When it comes to the capital structure of this company, Organogenesis Holdings Inc. [ORGO] has a Total Debt to Total Equity ratio set at 53.27. Additionally, ORGO Total Debt to Total Capital is recorded at 34.76, with Total Debt to Total Assets ending up at 26.43. Long-Term Debt to Equity for the company is recorded at 39.39, with the Long-Term Debt to Total Capital now at 25.70.
Reflecting on the efficiency of the workforce at the company, Organogenesis Holdings Inc. [ORGO] managed to generate an average of $19,724 per employee. Receivables Turnover for the company is 7.04 with a Total Asset Turnover recorded at a value of 1.31.Organogenesis Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.50.
Earnings analysis for Organogenesis Holdings Inc. [ORGO]
With the latest financial reports released by the company, Organogenesis Holdings Inc. posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 77.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ORGO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Organogenesis Holdings Inc. go to 44.46%.
Insider trade positions for Organogenesis Holdings Inc. [ORGO]
There are presently around $408 million, or 42.80% of ORGO stock, in the hands of institutional investors. The top three institutional holders of ORGO stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 2,995,638, which is approximately New of the company’s market cap and around 54.10% of the total institutional ownership; BLACKROCK INC., holding 2,290,580 shares of the stock with an approximate value of $37.54 million in ORGO stocks shares; and GRANAHAN INVESTMENT MANAGEMENT INC/MA, currently with $32.95 million in ORGO stock with ownership of nearly 35.06% of the company’s market capitalization.
Positions in Organogenesis Holdings Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 75 institutional holders increased their position in Organogenesis Holdings Inc. [NASDAQ:ORGO] by around 11,855,435 shares. Additionally, 24 investors decreased positions by around 8,342,470 shares, while 8 investors held positions by with 4,694,343 shares. The mentioned changes placed institutional holdings at 24,892,248 shares, according to the latest SEC report filing. ORGO stock had 40 new institutional investments in for a total of 6,415,509 shares, while 6 institutional investors sold positions of 395,457 shares during the same period.